Guess which small cap ASX share could rise 100%+

A leading broker is tipping big returns from this speculative stock.

| More on:
A person with a round-mouthed expression clutches a device screen and looks shocked and surprised.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Immutep Ltd (ASX: IMM) shares ended the week on a disappointing note.

The small cap ASX biotechnology share fell 3% to finish the session at 33 cents.

But its shares may not be trading at those levels for long if one leading broker is to be believed.

What is being said about this small cap ASX share?

Analysts at Bell Potter have been looking over a recent data update and were pleased with what they saw. Commenting on the INSIGHT-003 trial, the broker said:

IMM have provided a data update from the Phase 1 trial called INSIGHT-003 evaluating Efti in combination with Keytruda + chemo in first-line non-small cell lung cancer (1L NSCLC) patients. We consider the data to be a strong update and provides further support heading into the pivotal Phase 3 trial starting in the next few months using the same treatment regimen in a similar patient population.

Bell Potter highlights that the median survival data was strong and was a key highlight from the release. It adds:

A key highlight was the 32.9 months median survival for the first 21 patients, roughly 11 months longer than the 22.0 months observed for a similar patient group in the historical Keytruda + chemo Phase 3 trial (KEYNOTE-189). Additionally, the first 21 subjects showed favourable outcomes relative to the historical phase 3 trial in terms of (1) median progression-free survival (mPFS) of 12.7m vs. 9.0 months; and (2) 24- month survival rate of 81% vs 46%.

Big potential returns

According to the note, the broker has held firm with its speculative buy rating and 70 cents price target on the small cap ASX share.

This implies massive potential upside of 111% for investors over the next 12 months.

To put that into context, a $500 investment would be worth approximately $1,050 by this time next year if Bell Potter is on the money with its recommendation.

The broker acknowledges that there's still a lot of work to be done, but that the early signs are positive. It concludes:

While INSIGHT-003 is a relatively small trial lacking a head-to-head control arm, the data so far looks promising and provides added confidence in the upcoming Phase 3 trial (n=750) utilising the same treatment regimen. First-line NSCLC is one of the most lucrative oncology indications, and while the Ph3 will be a multi-year trial, there are futility and interim readout events along the way to maintain interest.

There are no changes to our forecasts after this data update. We maintain our BUY (spec.) recommendation and $0.70 valuation. Upcoming readouts in the next 12 months include: (1) further head & neck Ph2 data (Cohort B update on 12-Dec-2024, Cohort A survival data 2025); (2) Ph1 results with autoimmune drug candidate in healthy volunteers; and (3) Ph2 breast cancer results using the 90mg dose (having potential relevance for the Ph3 dose in 1L NSCLC).

Should you invest $1,000 in Apple right now?

Before you buy Apple shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Apple wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Small Cap Shares

A man slumps crankily over his morning coffee as it pours with rain outside.
Small Cap Shares

Why this Telstra-linked ASX small cap stock just crashed 90%

This small cap is having a very bad session. What's going on?

Read more »

A young boy wearing a hat, sunnies and striped singlet looks fierce and flexes his arm in victory.
Small Cap Shares

The ASX small-cap stock trading at 'half of the earnings multiple of industry leaders'

A leading fund manager sees a lot of untapped value for this soaring ASX small-cap stock.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Small Cap Shares

These small cap ASX stocks could rise 15% to 70%

Analysts think big returns could be on the cards for buyers of these stocks.

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
Small Cap Shares

2 under-$5 ASX hidden gems worth your attention

These buy-rated shares are flying under the radar. Let's see why analysts are bullish on them.

Read more »

Miner looking at a tablet.
Resources Shares

2 small-cap ASX mining shares exploding 40%+ on China tariff news

Investors are sending the small-cap ASX mining shares flying higher on Wednesday.

Read more »

Siblings jumping on a trampoline.
Small Cap Shares

3 ASX small-cap shares with a 'solid growth outlook' for 2025

A leading fund manager expects strong growth from these ASX small-cap stocks in 2025.

Read more »

A little girl with red hair runs excitedly with a rocket strapped to her back, trying to launch.
Small Cap Shares

Guess which ASX small-cap stock exploded 154% on big US news!

ASX small-cap stocks carry added risk, but also sometimes offer supersized rewards.

Read more »

A group of businesspeople clapping.
Healthcare Shares

This fund returned 109% in 2024. Here are 2 of its best-performing ASX shares

Small caps proved to be the winners last year.

Read more »